Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer

References

• Allinen M, Beroukhim R, Cai L, et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. (2011). Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95.
   PubMed Web of Science ®Google Scholar
• Chen HK, Zhang SM, Chang JL, et al. (2018). Insonation of systemically delivered cisplatin-loaded microbubbles significantly attenuates nephrotoxicity of chemotherapy in experimental models of head and neck cancer. Cancers (Basel) 10:311.
   PubMed Web of Science ®Google Scholar
• Chinnathambi S, Karthikeyan S, Kesherwani M, et al. (2016). Underlying the mechanism of 5-fluorouracil and human serum albumin interaction: a biophysical study. J Phys Chem Biophys 6:2161–398.
   Google Scholar
• Dalwadi C, Patel G. (2018). Thermosensitive nanohydrogel of 5-fluorouracil for head and neck cancer: preparation, characterization and cytotoxicity assay. Int J Nanomedicine 13:31–3.
   PubMedGoogle Scholar
• Danneberg PB, Montag BJ, Heidelberger C. (1958). Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo. Cancer Res 18:329–34.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–47.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Harris BE. (1989). Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–37.
   PubMed Web of Science ®Google Scholar
• Diasio RB, Lu Z. (1994). Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12:2239–42.
   PubMed Web of Science ®Google Scholar
• Draper AS, Lafollette J, Kim C, et al. (2021). Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion. J Oncol Pharm Pract 27:1159–64.
   PubMed Web of Science ®Google Scholar
• Falco A, Leiva M, Blanco A, et al. (2022). First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: a multicenter cohort study. World J Clin Oncol 13:147–58.
   PubMed Web of Science ®Google Scholar
• Feng L, Dong Z, Tao D, et al. (2018). The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Nat Sci Rev 5:269–86.
   Web of Science ®Google Scholar
• Fujii S, Ikenaka K, Fukushima M, et al. (1978). Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan 69:763–72.
   PubMedGoogle Scholar
• Gerweck LE, Seetharaman K. (1996). Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56:1194–8.
   PubMed Web of Science ®Google Scholar
• Grem JL. (2000). 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299–313.
   PubMed Web of Science ®Google Scholar
• Ibrahim B, Mady OY, Tambuwala MM, et al. (2022). pH-sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer. Nanomedicine (Lond) 17:367–81.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Utoh M, Sawada N, et al. (1998). Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–7.
   PubMed Web of Science ®Google Scholar
• Kim JW, Dang CV. (2006). Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–30.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Beumer JH, Chu E. (2016). Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78:447–64.
   PubMed Web of Science ®Google Scholar
• Liao AH, Li YK, Lee WJ, et al. (2012). Estimating the delivery efficiency of drug-loaded microbubbles in cancer cells with ultrasound and bioluminescence imaging. Ultrasound Med Biol 38:1938–48.
   PubMed Web of Science ®Google Scholar
• Liao AH, Lin KH, Chuang HC, et al. (2020). Low-frequency dual-frequency ultrasound-mediated microbubble cavitation for transdermal minoxidil delivery and hair growth enhancement. Sci Rep 10:4338.
   PubMed Web of Science ®Google Scholar
• Meirovitz A, Bergerson S, Hirshoren N, et al. (2022). Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients. Cancer Rep (Hoboken) 5:e1479.
   PubMedGoogle Scholar
• Rades D, Seidl D, Janssen S, et al. (2016). Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? Oral Oncol 57:40–5.
   PubMed Web of Science ®Google Scholar
• Rohani N, Hao L, Alexis MS, et al. (2019). Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Res 79:1952–66.
   PubMed Web of Science ®Google Scholar
• Scaglione F, Panzavolta G. (2014). Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica 44:480–8.
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Hohneker J, Ratain MJ, et al. (1998). Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16:1450–7.
   PubMed Web of Science ®Google Scholar
• Sephra NR. (2012). Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors (Basel) 12:12347–60.
   PubMed Web of Science ®Google Scholar
• Sethy C, Nath Kundu C. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother 137:111285.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kaur A, Jain UK, et al. (2017). Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells. Colloids Surf B Biointerfaces 155:200–8.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Nakano K, Takechi T, et al. (1996). Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602–6.
   PubMed Web of Science ®Google Scholar
• Wang N, Wang T, Wang M, et al. (2011). Using ultrafiltration to facilitate simultaneous quantification of 5-fluorouracil in mouse plasma and tissues by HPLC. J Liq Chromatogr Relat Technol 34:2033–47.
   Web of Science ®Google Scholar
• Whiteside T. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904–12.
   PubMed Web of Science ®Google Scholar
• Zou W, Huang C, Sun Q, et al. (2022). A stepwise mutagenesis approach using histidine and acidic amino acid to engineer highly pH-dependent protein switches. 3 Biotech 12:21.
   PubMedGoogle Scholar